To identify clinically meaningful development directions for strategies intended to overcome the limitations of PD-1/PD-L1 inhibitor therapy and generate practice-relevant late-phase readouts through 2030.
Approach:
Registry-derived analysis: The study involved a structured narrative review using registry-derived data, focusing on late-phase clinical programs and applying a two-level interpretive framework.
Key Findings:
Durable benefit from PD-1/PD-L1 inhibitors is limited to specific patient subgroups and clinical settings.
A total of 47 clinically relevant late-phase programs were identified from over 13,000 studies.
A narrower subset of programs was highlighted for their potential to test incremental clinical benefit in comparative designs.
Interpretation:
The review provides a framework for prioritizing future translational and late-phase efforts in PD-1/PD-L1 therapy development.
Limitations:
The analysis does not constitute a full systematic review or meta-analysis.
Registry indexing is dynamic, which may affect the availability of data and the comprehensiveness of the analysis.
Conclusion:
The review identifies promising strategies for PD-1/PD-L1 therapy development.
